During a live event, Andrew H. Lipsky, MD, and participants weigh acalabrutinib, zanubrutinib and pirtobrutinib, comparing real-world side effects, cardiac risks, and dosing tradeoffs.
Patients With Treatment-Naïve CLL Treated With BTK Inhibition
During a live event, Andrew H. Lipsky, MD, and participants discuss emerging trial data and real-world applications of innovative CLL treatment combinations.
During a live event, Mazyar Shadman, MD, MPH, discussed zanubrutinib’s long-term outcomes in CLL for high-risk patients.
During a live event, Mazyar Shadman, MD, MPH, discussed options for a patient with high-risk CLL as recommended by the NCCN guidelines.
During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal patient selection for CLL.
During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences when choosing CLL treatment.
During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.
During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD following fixed-duration treatment of chronic lymphocytic leukemia.
During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax might be used in patients with chronic lymphocytic leukemia.
During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.
During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic lymphocytic leukemia who received 1 prior line of therapy in the first article of a 2-part series.
During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed subgroup analyses and adverse events from the ALPINE trial of zanubrutinib for a patient with relapsed/refractory chronic lymphocytic leukemia in the second article of a 2-part series.
During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
In the first article of a 2-part series, Marc S. Hoffmann, MD, looks at the factors to take into consideration before initiating another line of treatment in patients with chronic lymphocytic leukemia.
In the second article of a 2-part series, Sameer A. Parikh, MBBS, looks at the risk of cardiac related toxicities with zanubrutinib for patients with relapsed chronic lymphocytic leukemia.
In the first article of a 2-part series, Sameer A. Parikh, MBBS, discusses the makeup and design of the phase 3 ALPINE study that showed the promise for the next-generation Bruton tyrosine kinase inhibitor zanubrutinib.
In the second article of a 2-part series, William G. Wierda, MD, PhD, looks at the efficacy and safety outcomes with the second generation BTK inhibitor zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
In the first article of a 2-part series, William G. Wierda, MD, PhD, discusses the role Bruton tyrosine kinase inhibitors play in the relapsed/refractory chronic lymphocytic leukemia setting.